--- a
+++ b/clusters/3009knumclusters/clust_46.txt
@@ -0,0 +1,752 @@
+Platelet count > 100,000/mm^3 =< 2 weeks prior to randomization
+Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC] transfusions)
+For patients with solid tumors without known bone marrow involvement: \r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)
+Platelet count ? 60,000/mm3
+* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8 g/dL
+Within 6 weeks prior to randomization: Platelet count must be >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+STEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)
+Platelet count > 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Re-registration: platelet count >= 100,000/mm^3
+Platelet count >= 100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 prior to registration
+Platelet count >= 100,000/mm^3
+Within 14 days of registration: Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Obtained within 28 days prior randomization: platelet count must be >= 100,000/mm^3
+Platelet count >= 100,000/mm^3, within 4 weeks of randomization
+Platelet (PLTs) count >= 100,000/mm^3 obtained =< 21 days prior to registration
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count of >= 100,000/mm^3
+Platelet count ? 75 x 10^9/L (75,000/mm3)
+Obtained =< 21 days prior to registration: Platelet (PLT) >= 100,000/mm^3
+Platelet count ? 75,000/mm3
+Platelet count >= 75,000/ mm^3 (=< 28 days prior to registration)
+Obtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count ? 75,000 cells/mm3 (75 x 109/L)
+Platelet count 100,000 (plt/mm3)
+Platelet count at least 100,000/mm3.
+Platelet count must be greater than or equal to 100,000/mm3; and
+Platelet count > 25,000/mm3
+Platelet count > 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3, performed within 14 days of treatment initiation
+Platelet count >= 50,000/mm^3; note: platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 50,000/mm^3
+Platelet count >= 100,000 per mm^3
+Platelet count <150,000/mm3
+Platelet count ? 100,000/mm^3
+Within 10 (except as noted) days of planned treatment initiation: Platelet count >= 100 × 10^9/L (>= 100,000 per mm^3)
+platelet count must be ? 100,000/mm3; and
+Platelet count ? 75,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000 mm^3 within 14 days of enrollment to trial
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count is >= 50,000/mm^3 (<= 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count of >= 100,000/mm^3 before starting therapy
+Evident myeloid and platelet engraftment: Absolute neutrophil count (ANC) > 1000/mm^3 and platelet count > 25,000/ mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 100,000/mm^3 (100 x 10^9/L). Must not have required transfusion of platelets within 1 week of baseline platelet count assessment.
+Platelet count >= 100,000 platelet/mm^3 (100 × 10^9/L)
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000 cells/mm^3 (50 x 10^9/L) at least 3 weeks prior to screening unless attributable to disease; platelet count >= 20,000 cells/mm^3 is permissible if due to disease
+Obtained =< 35 days prior to registration: platelet count >= 100,000/mm^3
+Platelet count ? 100,000 cells/mm3
+Platelet count >= 100,000 /mm^3
+Platelet count > 50,000 cells/mm^3 (50 x 10^9/L)
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 100,000/mm^3 (performed within 14 days of treatment initiation)
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 50,000/mm^3, obtained =< 14 days prior to registration
+Platelet count > 100,000/mm^3
+Platelet count > 100,000 cells/mm^3
+Platelet count > 100000 /mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3 =< 28 days prior to registration
+Absolute neutrophil count (ANC) ? 1,000/mm^3 without growth factor support and platelet count ? 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization.
+Platelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50,000 cells/mm^3
+Platelet count >= 50,000/mm^3 in the absence of bone marrow involvement; patients with bone marrow involvement only require a platelet count of >= 30,000/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count (PLT) > 100,000/mm^3
+Platelet count >100,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Obtained =< 14 days prior to registration: Platelet count >= 75000/mm^3
+Platelet count >= 100,000/mm^3
+PART I: Platelet count >= 75,000/mm^3
+PART II: Platelet count >= 75,000/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).
+Platelet count >= 100,000/mm^3
+Should be performed within 10 days of treatment initiation: platelet count ? 100 x 10^9/L (?100,000 per mm^3)
+Platelet count >= 50,000/mm^3
+Platelet count ?100,000/mm3
+Obtained ? 14 days prior to registration: Platelet count ? 75000/mm^3; Note: Platelet transfusion is not allowed ? 3 days prior to registration
+Platelet count < 50,000/mm^3, per PI discretion if thought to be related to underlying myeloma
+Platelet count ? 75,000 cells/mm3 (75 x 109/L) (without required transfusions during the 10 days prior to initiation of therapy)
+Evidence of mucosal or internal bleeding and/or are platelet transfusion refractory (i.e. platelet count fails to increase by > 10,000 cells/mm3 after transfusion of an appropriate dose of platelets)
+Platelet count >= 100,000/mm^3
+Platelet count ? 100,000/mm^3
+Platelet count of > 100,000/mm^3L
+Platelet count >= 25,000/mm^3
+Platelet count less than 100000/mm^3
+Platelet (Plt) < 120,000/mm^3
+Within 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Platelet count >= 100,000/mm^3.
+Platelet count ? 100,000/mm3 without transfusion.
+STRATUM A: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the test
+STRATUM B: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the test
+STRATUM C: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the test
+Platelet count (PLT) >= 75,000/mm^3 (measured within 28 days of registration)
+Platelet count greater than 100,000/mm^3
+Obtained within 21 days prior to cycle 1, day 1: platelet count >= 75,000/mm3
+Platelet count >= 50,000/mm^3
+COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)
+COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)
+COHORT 3: ENDOMETRIAL CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 75,000/mm^3 within 90 days prior to randomization
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Platelet count >= 100,000/mm^3
+Platelet count ? 100,000/mm^3 (100 × 10^9/L) obtained ? 14 days prior to randomization
+Platelet count < 50,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count >= 100,000/mm^3 obtained =< 14 days prior to registration
+Platelet count >= 100 000/mm3 (within 16 days before starting therapy)
+Platelet count >= 100 000/mm^3 (within 16 days before starting therapy)
+Platelet (PLT) count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Obtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count ? 100,000 cells/mm^3
+Platelet count >= 75,000/mm^3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 100,000/mm^3
+Obtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Within 7 days prior to administration of study treatment: Platelet count >= 100 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case platelet >=50,000/ mm^3 is allowed).
+Platelet count >= 75 x 10^9/L (> 75,000 per mm^3)
+Platelet count ? 100,000/mm3 (transfusion independent defined as no platelet transfusion within 7 days and recovery from nadir)
+Platelet count >= 75,000 cells/mm^3 (75 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
+Platelet count >= 100,000/mm^3
+Platelet count at least 100,000/mm^3 or at least 100 x 10^9/L
+Within 7 days (+ 3 day window) of enrollment: Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>100,000 per mm^3).
+Platelet count > 50,000 cells/mm^3 (50 x 10^9/L)
+Obtained =< 28 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^2
+Platelet count >= 100,000/mm^3
+Platelet count ?100,000 /mm3;
+Platelet count >= 100,000/mm^3
+Platelet count of > 100,000/mm^3
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Compromised hematopoietic function (hemoglobin <8.0 g/dL; lymphocyte count <300 mm3; neutrophil count <1000 mm3; platelet count <100,000 mm3).
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count < 100,000/mm^3 at the time of screening
+Platelet count >= 50,000/mm^3
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Patients with lack of count recovery as defined by ANC > 500 cells/mm^3, non-transfused platelet count > 20,000 K/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count greater than 75,000/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet >= 30,000 cells/mm^3
+Platelet count < 75,000 mm3 without transfusion support within 7 days prior to testing
+Platelet count > 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Platelet count >= 100,000/mm^3 (transfusion independent defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) within 14 days of registration
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count <100,000/mm3
+Platelet >100,000/ mm3
+Platelet count >= 100,000/mm^3 obtained =< 7 days prior to registration
+Platelet >= 30,000/mm^3 without transfusion or growth factor support for at least 1 week
+Determined within 3 weeks of treatment initiation: Platelet count >= 75,000/mm^3 (75 x 10^9/L)
+Platelet count ? 50,000/ mm^3
+Platelet count >= 100,000/mm^3 (within 16 days of enrollment)
+Platelet count < 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 75,000/mm^3
+Platelet count >= 75,000/mm^3 obtained =< 14 days prior to registration
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3).
+FULL STUDY INCLUSION CRITERIA: Platelet count >= 75,000/mm^3, without platelet transfusion within 3 weeks before the start of study treatment
+Platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration)\r\n* Criteria must be met without a transfusion within four weeks of registration
+Platelet count of >= 100,000/mm^3 (Note: Transfusion or growth factor may be used for eligibility outside of 7 days)
+Platelet count >=25,000/mm^3 [25 x 10^9/L]
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3) within 28 days prior to study registration
+Untransfused platelet count >= 75000/mm^3, obtained =< 14 days prior to registration
+Obtained =< 7 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 obtained =< 14 days prior to registration
+Platelet count >= 75 x 10^9/L (>= 75,000 per mm^3)
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)
+Platelet count > 75,000 cells/mm^3 (75 x 10^9/L)
+Platelet count of >= 100,000/mm^3
+Platelet count >= 75,000 (platelets [plt]/mm^3), (CTCAE grade 1 baseline)
+Platelet count >= 100,000/mm^3
+Platelet count > 100,000 cells/mm^3
+Platelet (PLT) >= 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Within 60 days prior to registration, hematologic minimal values: platelet count > 100,000/mm^3
+Platelet count > 50,000 cells/mm^3 (50 x 10^9/L)
+Platelet count >= 100,000/ mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>100,000 per mm^3)
+Obtained =< 14 days prior to randomization: Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count < 100,000/mm^3
+Completed within 60 days of surgery: Platelet count ? 100,000/mm
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 90 x 10^9/L (100,000/mm^3)
+Platelet count >= 100,000/mm^3
+PART 2 GROUP 1 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+PART 2 GROUP 3 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000 (platelet [plt]/mm^3), with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, the platelet count should be > 3 0,000 plt/mm^3 (transfusion support or growth factor support is acceptable)
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Platelet count >= 50,000/mm^3
+Platelet count < 100,000/mm^3
+EXCLUSION CRITERIA FOR TNBC: Platelet count < 75,000/mm^3
+Platelet count greater than or equal to 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 75000/mm^3
+PRIOR TO LYMPHODEPLETION: Platelet count > 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Obtained =< 14 days prior to registration: Platelet count >= 30,000/mm^3
+Platelet count >= 100,000 /mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count (transfusion independent) >= 75,000/mm^3
+Platelet count ? 100 x 10^9/L (? 100,000 per mm^3)
+Platelet count >= 100,000/mm^3
+Platelet count >= 70,000 cells/mm^3 if marrow plasmacytosis < 50%; platelet count >= 30,000 cells/mm^3 if marrow plasmacytosis >= 50%
+Bone marrow: hemoglobin ? 10 g/dL, platelet count ? 100,000/mm3, absolute neutrophil count ? 1,500/ mm3, absolute lymphocyte count ? 500/ mm3.
+Adequate hematological function, defined as ANC ? 1,500/mm3, Hb ? 9.0 g/dL, and platelet count ? 100,000/mm3.
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment \r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 75,000/mm^3, obtained =< 7 days prior to registration
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment
+Platelet counts > 100,000/mm^3 (without support)
+Platelet count >= 75,000/mm^3
+Platelet count < 100,000 per mm^3
+ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Platelet count >= 100,000/mm^3
+Platelet count > 100,000/mm^3 (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 20,000/mm^3; these patients should be discussed with either the PI or Co-PI of the study for final approval)
+Platelet count ? 75,000/mm3;
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 (no transfusion within 7 days of enrollment)
+For subjects with solid tumors without known bone marrow involvement: platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count ? 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count ? 100,000/mm³.
+Platelet (PLT) count >= 100,000/mm^3
+Platelet count > 100,000/mm^3; independent of transfusion
+Platelet count >= 100,000/mm^3 or >= 75,000/mm^3 if thrombocytopenia is attributed to B-NHL (involvement of bone marrow or due to splenomegaly or immune thrombocytopenic purpura); platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 30,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 40 x 10^3/mm^3 (may be post-transfusion)
+Platelet count >= 100,000/mm^3
+platelet count must be greater than or equal to 100,000/mm3; and
+Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
+Platelet count >= 90,000/mm^3
+Platelet count =< 100,000 per mm^3
+Within 2 weeks of enrollment: Platelet count, >= 100,000 cells/mm^3
+Within 30 days of first vaccination: Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count < 75,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 platelet/mm^3 (100 × 10^9/L)
+Platelet count > 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 (100 × 10^9/L)
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet >= 75,000 cells/mm^3
+Platelet count >= 100,000 cells/mm^3
+Relapsed/refractory MCL: Platelet count >= 30,000/mm^3 (transfusion to reach platelet count allowed); (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 15,000/mm^3; these patients should be discussed with either the PI or Co-PI of the study for final approval)
+Newly diagnosed MCL: Platelet count > 50,000/mm^3; patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 15,000 /mm^3; (platelet transfusions are allowed; these patients should be discussed with either the PI or Co-PI of the study for final approval)
+Platelet count of > 100,000/mm^3
+Platelet count >= 100,000 per mm^3 AND
+Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
+Platelet count ? 75,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count of >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000 /mm^3
+Platelet count >= 75,000/mm^3 obtained =< 14 days prior to registration
+Platelet count (PLT) >= 100,000/mm^3
+Platelet count >= 50,000 cells/mm^3 (50 x 10^9/L), at screening
+Platelet count of >= 100,000/mm^3
+Platelet count > 100,000/mm^3
+Absolute neutrophil count < 1500 per mm3 or platelet count < 100,000 per mm3 if getting chemotherapy concurrent with radiation
+Platelet count >= 100,000/mm^3
+Platelet count >= 30,000/mm^3
+Hematopoietic Function: WBC ? 2,500/mm3; ANC ? 1000/mm3; Hemoglobin ? 8 g/dL; Platelet count ? 50,000/mm3; Coagulation: INR ? 1.3.
+Platelet count >= 100,000/mm^3 within 7 days prior to starting treatment
+Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3 and platelet count of >/= 100,000 cells/mm3;
+Platelet > 125,000 platelet/mm^3
+Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.
+Platelet count < 100,000 cells/mm3.
+Platelet count ?75,000/mm3.
+Platelet count >= 50,000/mm^3 obtained =< 14 days prior to registration
+Platelet count >= 75000/mm^3, obtained =< 14 days prior to registration
+Platelet count >= 100,000/mm^3 (repeat if more than 3 days before the first dose)
+Platelet count must be greater than or equal to 75,000/mm3; and
+Platelet count ? 30,000/mm3 (75 x 109/L)
+Platelet count >= 50,000 mm^3; platelet count should be independent of transfusions for at least 14 days for eligibility
+Platelet count ? 100,000/mm3 (IU: ? 100 × 109/L) (excluding measurements obtained within 7 days after a transfusion of platelets).
+Platelet count < 50,000 cells/mm3
+ANC > 1500/mm3, plt count > 100,000/mm3
+Hematology: ANC >1500 cells/mm3, platelet count >100,000 cells/mm3 and Hemoglobin > 9 gm/L
+Platelet count >50,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count ?100,000/mm3
+Platelet count ? 100,000/mm^3
+Within 14 days prior to randomization: Platelet count must be >= 100,000/mm^3
+Platelet count ?100,000 cells/mm3
+Platelet count >= 100,000/mm^3
+Platelet count ?100,000 cells/mm3
+Platelet count >= 75 mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment
+Platelet count greater than 75,000/mm³
+Platelet count >= 75,000 /mm^3 within 28 days prior to registration.
+For subjects with solid tumors without known bone marrow involvement: \r\n*Platelet count ? 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Obtained ? 14 days prior to registration: platelet count ? 75,000/mm^3 (NOTE: platelet transfusions in order to help patients meet eligibility criteria are not allowed)
+Platelet count >= 100,000/mm^3.
+Platelet count >= 100,000/mm3
+Platelet count >= 100,000/mm^3 and no transfusion in prior 4 weeks, within 28 days of day 0.
+Platelet count ? 100,000 cells/mm^3 ? 2 weeks
+Obtained =< 21 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count >= 75 x 10^9/L (>=100,000 per mm^3).
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3), except for patients with HCC for whom a platelet count > 60,000 per mm^3 is allowed
+Platelet count > 100,000/mm^3. Patients who have bone marrow infiltration by MCL are eligible if their platelet level is >= 50,000 /mm^3 independent of platelet transfusions.
+Platelet count >= 75,000/mm^3
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Platelet count >= 100,000 per mm^3
+Platelet count >= 100,000 /mm^3
+Platelet count >= 100,000 /mm^3
+Platelet count >= 100,000 /mm^3
+For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count > 100,000/mm3
+Platelet count >= 100,000/mm^3
+Within 7 days prior to study registration: Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3 (100 x 10^9 /L) obtained =< 28 days prior to registration
+Platelet count >= 25,000/mm^3 [25 x 10^9/L],
+Platelet count >= 100,000 plt/mm^3
+Platelet count >= 100,000/mm^3, obtained =< 7 days prior to registration
+Platelet count >= 100,000/mm^3
+Platelet count must be >= 100,000/mm^3 within 28 days before randomization
+Performed within 14 days prior to study: Platelet count >= 100,000/mm^3
+Platelet count < 100,000/mm^3, or
+Platelet count > 100,000/mm^3
+Platelets >= 100,000/mm^3 (transfusion independent (except for patients with marrow involvement by disease where there is no blood count requirement, except for platelet count which must be >= 25,000 prior to enrollment (can be achieved with transfusion)
+Platelet count >= 50,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); in NB patients with known bone marrow involvement relaxed platelet count eligibility requirement should be used: a platelet count of >= 20,000/mm that can be maintained with =< 1 platelet transfusion per week
+ARM A: obtained =< 14 days prior to registration: \r\n* Platelet count >= 80,000/mm^3
+ARM B: obtained =< 14 days prior to registration: \r\n* Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 or >= 100 x 10^9/L (must be >= 7 days after most recent transfusion), obtained =< 14 days prior to registration
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet >= 100,000/ mm^3
+Lymphocyte count >= 400/mm^3
+Platelet count >= 75,000/mm^3
+Obtained =< 7 days prior to registration: Platelet count >= 100,000/mm^3
+Platelet count (PLT) >= 100,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)
+Platelet count >= 100,000 per mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count >= 75000/mm^3
+Platelet count > 100,000 cells/mm^3
+Platelet count >= 75,000 /mm^3
+Platelet count >= 100,000/mm^3 (obtained =< 14 days prior to registration)
+Platelet count >= 100,000/mm^3 or >= 100 x 10^9/L
+Platelet count >= 100,000/mm^3
+Platelet count (PLT) > 100,000/mm^3
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count must be >= 50,000/mm^3 (not achieved by transfusion)
+Platelet count >= 100,000 cells/mm^3
+Platelet count must be >= 100,000/mm^3
+Platelet count < 100,000 / mm^3
+Platelet count >= 100,000/mm^3
+Platelet count greater than 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+For patients with solid tumors or ALCL without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count must be >= 75,000/mm^3 (not achieved by transfusion) unless due to underlying disease in which case there is no grade restriction
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Patients on Part A1 or Part C of the study:\r\n* For patients with solid tumors or ALCL without bone marrow involvement:\r\n** Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3\r\n** Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)\r\n** Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)\r\n* Patients with known bone marrow metastatic disease: \r\n** Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n** Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n** Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n** Not known to be refractory to RBC or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteria; Note: patients with known bone marrow metastatic disease are not evaluable for hematological toxicity for the purposes of dose escalation
+Patients eligible for Part A2, Part A3, or Part B of the study must meet the hematologic criteria below for enrollment:\r\n* Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n* Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n* Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n* Not known to be refractory to red cell or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteria
+Platelet count >= 130,000/mm^3
+Platelet count >= 100,000/mm^3 within four weeks prior to randomization
+Platelet count < 50,000/mm^3 within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count < 30,000/mm^3 for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; transfusion is not allowed to meet platelet eligibility criteria
+For RCC, platelet count ?80,000 cells/mm3
+Platelet count ?75,000 (plt/mm3) (CTCAE Grade 1 baseline)
+Platelet count ? 100,000 cells/mm3
+Platelet count >= 100,000/mm³
+Platelet count >= 100,000/mm^3, obtained =< 21 days prior to registration
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count ? 100,000/mm^3
+platelet count must be greater than or equal to 100,000/mm3; and
+SUB-PROTOCOL AIM A: Platelet count >= 100,000/mm^3
+Platelet count > 100,000 cells/mm^3
+Platelet count at least 100,000/mm3
+Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Platelet count >= 100 K/mm^3
+Platelet count ? 100,000/mm3
+Platelet count >= 100,000/mm^3
+Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000 cells/mm^3
+Platelet count >= 100,000 cells/mm^3
+Platelet count of >30,000/mm3
+Platelet count >= 75,000/mm^3
+Platelet count greater than or equal to 100,000/mm^3
+Platelet count ? 7.5 x 104 /mm3
+Lymphocyte count ? 500/mm3
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count > 100,000/mm^3
+Platelet count less than 100,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet >= 100,000/ mm^3
+Platelet count >= 100,000 cells/mm^3
+Platelet count >= 100,000/mm^3 (transfusion independent)
+Platelet count >= 75,000/mm^3 obtained =< 7 days prior to registration
+Within 14 days of enrollment: Lymphocyte count >= 300/mm^3
+Platelet count ? 75 x 10^9/L (75,000/mm3)
+Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Platelet >= 100 x 10^9/L (> 100,000 per mm^3), obtained within 14 days prior to first treatment
+Platelet count >= 100 000/mm^3 (within 16 days before starting therapy)
+Platelet count > 30,000/mm^3
+Platelet count < 50 x109/L (< 50,000 cells/mm3)
+Platelet count >= 75,000/mm^3; platelet transfusions are not allowed within 3 days before study enrollment
+Subjects with evidence of mucosal or internal bleeding and/or platelet refractory (i.e., unable to maintain a platelet count >= 50,000 cells/mm^3)
+Platelet count: ? 100,000/mm3
+Platelet count =< 70,000/mm^3
+Platelet count > 50,000/mm^3
+Platelet count >= 100,000/mm^3 obtained =< 14 days prior to registration
+Platelet count ? 50,000/mm3 (? 30,000/mm3 if myeloma involvement in the bone marrow is > 50%. Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.)
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Platelet count < 75,000 cells/mm^3 at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within 7 days of obtaining screening evaluation
+Platelet count > 100,000/mm^3 (obtained =< 7 days prior to randomization)
+Platelet (PLT) count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 obtained =<14 days prior to randomization
+Platelet count >= 100,000/mm^3
+Platelet count (PLT) >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) and
+Platelet count > 75,000/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 1000/mm^3 [growth factor not allowed] or their platelet level is >= 50,000/mm^3)
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 40 x 10^3/mm^3 (may be post-transfusion)
+Platelet (PLT) >= 100,000/mm^3
+PHASE I: Platelet count >= 50,000 mm^3
+PHASE II: Alternatively, with less BM involvement, an ANC >= 1000/mm^3, and platelet count >= 50,000 mm^3 is required
+Absolute neutrophil count (ANC) ? 1,000 per cubic milliliter (/mm^3) and platelet count ? 75,000/mm^3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before randomization.
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criterion will not be allowed
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+platelet count > 100,000/mm3
+Platelet count of < 100,000/mm^3
+Platelet count < 100,000/mm^3
+Platelet count ? 100,000/mm3
+Platelet count >= 50,000/mm^3
+Platelet count < 75,000/mm^3
+Platelet count < 75,000 cells/mm^3 at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within 7 days of obtaining screening evaluation
+Platelet count greater than 50,000/mm3 within 8 weeks prior to initial cryoablation procedure.
+Within 30 days prior to initiation of protocol treatment: Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be 50,000 cells/mm^3
+Platelet count must be > 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
+Platelet count of >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm3
+Platelet > 100,000/mm^3
+Platelet count >= 100,000/mm^3 (unsupported)
+Platelet count >= 100000/mm^3 (within 16 days before starting therapy)
+Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
+Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
+Platelet count of more than 100,000/mm^3
+Platelet count >= 100,000 cell/mm^3
+Obtained within 2 weeks from study entry: Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 75,000/mm^3
+Platelet count >= 75,000/mm^3
+STEP 2 ENROLLMENT AND RANDOMIZATION: platelet count >= 100,000/mm^3 within 3 weeks of study entry
+Platelet count >= 100,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Within one week of study entry: Platelet count at least 100,000 cells/mm^3
+Platelet count >= 75,000/mm^3
+Absolute neutrophil count (ANC) ? 1000/mm^3 and platelet count ? 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria were not allowed within 3 days prior to randomization.
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3 obtained =< 14 days prior to randomization
+Platelet count ? 100,000 /mm3
+Platelet count >= 50,000 /mm^3
+Platelet count at least 80,000 cells/mm^3
+Platelet count at least 100,000/mm3
+Platelet count > 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > = 75,000 /mm³
+Platelet count >= 100,000/mm^3
+Platelet count of >= 100,000/mm^3
+Lymphocyte count >= 400/mm^3
+Platelet Count >= 50,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count greater than 75,000/mm^3
+Platelet count >= 100,00 mm^3 independent of transfusion support
+Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >= 100,000cells/mm3 Hemoglobin >=9.0g/dL
+Platelet count of >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count at least 100,000/mm^3 or at least 100 x 10^9/L
+Platelet count > 75000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count of  >= 100,000/mm^3
+Platelet count >= 20,000/mm^3 without transfusion support and no abnormal bleeding
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count ?75 x 109/L (?75,000/mm3)
+Platelet count > 100,000 cells/mm3, hemoglobin > 9 g/dL, absolute neutrophil count > 1,500 cells/mm3
+Platelet >= 100 x 10^9/L (> 100,00 per mm^3), obtained within 14 days prior to first treatment
+Platelet count < 50,000 cells/mm^3 (50 x 10^9/L) independent of transfusion support
+Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)
+Platelet count >= 100,000/mm^3
+Platelet >= 75,000/mm^3
+Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >=100,000cells/mm3 Hemoglobin >=9.0g/dL
+Platelet count ? 75,000/mm3 Arms B, C, and D must meet the following criteria:
+Platelet count ? 75,000/mm3
+Platelet >= 100,000/mm^3
+Platelet count >= 90,000/mm^3 (part 1 & 2)
+Platelet count greater than or equal to 50,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 /mm^3
+Platelet count >= 50,000/mm^3
+Platelet count ? 7.5 x 104 /mm3
+Platelet count ? 100,000 cells/mm3
+Platelet count ?100,000 //mm3 (?100 × 109/L).
+Platelet count equal or greater than 50,000 mm^3 independent of platelet transfusion
+Platelet count >= 75,000/mm^3 (unsupported)
+Platelet count ? 7.5 x 10^4/mm^3
+Platelet count >= 75,000/mm^3 (without platelet transfusion or myeloid growth factor support within two weeks of screening)
+Patients must have platelet count >= 10,000/mm^3 within 72 hours of initiating the induction cycle (for patients with platelets < 10,000/mm^3 at baseline, platelet transfusion support is allowed which is institutional standard of care for AML)
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >10,000 cells/mm3 (10 x 109/L)
+Platelet count >= 100,000/mm^3
+Platelet count >= 50,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count > 100,000 /mm^3
+Platelet count >= 50,000/mm^3
+Platelet count ? 100,000 (100 × 109/L) cells/mm3;
+Platelet count >= 100000/mm^3
+Platelet count > 75,000/mm^3
+Platelet >= 100,000/mm^3
+Platelet count >= 100000/mm^3
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count > 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+DONOR: platelet count 150,000 to 440,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 50,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count must be >= 75,000/mm^3 (not achieved by transfusion)
+Platelet count >= 100,000/mm^3
+Platelet Count > 100,000/mm3
+A platelet count of more than 100,000/mm^3
+TREATMENT: Platelet count greater than 100,000/mm^3
+Platelet count >= 100,000 cells/mm3 without transfusion or growth factor requirement
+Platelet count >= 100,000 cells/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count >= 100,000 platelets/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 platelets/mm^3
+Platelet count ? 100,000 cells/mm3 (100 x 109/L) or ? 50,000 cells/mm3 (50 x 109/L) if secondary to bone marrow involvement by disease.
+Platelet count must be >= 100,000/mm^3
+Platelet count >= 50 x 10^3/mm^3
+Platelet count ?75,000/mm³
+Platelet count < 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count equal to or less than 100,000/mm3
+Platelet count ? 100,000/mm3 (without platelet transfusion or growth factor support in the preceding 7 days);
+Platelet count greater than or equal to 100,000/mm^3
+Platelet count at least 100,000 cells/mm^3
+Platelet count of >= 100,000 mm^3
+Platelet count >= 75,000/ mm^3 (transfusion independent for > 7 days)
+Platelet count ? 100,000/mm3
+Platelet count ? 100,000 cells/mm3
+Platelet count 100.000 cells/mm3 (100 x 109/L)
+Platelet count >100,000 cells/mm3
+Platelet count >= 70 K/mm^3 un-transfused
+Platelet count > 75,000 mm^3
+Platelet count >= 130/mm^3
+Platelet count >= 100,000 cells/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count < 100,000 / mm^3
+Platelet count > 50,000/mm^3
+Platelet count < 100,000/mm3.
+Platelet count >= 100000/mm^3
+Platelet count >= 100,000/mm^3 within 16 days of starting therapy
+Platelet count > 100,000/mm^3
+Platelet count < 75,000 mm3 without transfusion support within 7 days prior to testing
+Platelet count >=100,000/mm^3
+Patients should have adequate bone marrow function defined as a peripheral WBC >3,000/mm3 with an ANC >1500/mm3 and a platelet count >100,000/mm3.
+Platelet count ? 100,000/mm3
+Platelet count ³ 100 × 109/L (100,000/mm3)
+Does the subject have a platelet count ? 100,000/mm3?
+Platelet count ? 100,000/cubic millimeters (mm3), hemoglobin (Hb) ? 8.5 g/dl, leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) ? 1,000/mm3
+Hematology: ANC >1500 cells/mm3, platelet count > 150,000 cells/mm3 and Hemoglobin > 9 g/dL
+Platelet count < 100,000 per mm3
+Platelet count > 75,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count > 100,000/mm^3
+Known platelet disorder, such as von Willebrand’s disease or baseline platelet count of < 100,000/mm^3
+Platelet count < 100,000 per mm3
+Platelet count ? 100,000/mm3.
+Platelet count >= 100,000/mm^3
+Platelet count >= 25000/mm^3
+Platelet count >= 100000/mm^3
+Cohort A: Platelet count greater than 100,000/mm^3
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3 (100 x 10^9/L)
+Platelet count >= 100,000/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet Count ? 100,000/mm3
+Platelet count ? 50,000/mm³ (? 30,000/mm³ if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization. Patients should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.
+Platelet count >100,000/mm3.
+Peripheral platelet count (PLT) >= 75,000/mm^3
+Platelet count =< 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 cells/mm^3
+platelet count > 100,000/mm^3
+Platelet >= 100,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 80,000/mm^3
+Platelet >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 mm^-3
+Platelet count >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement independent of transfusion support in either situation
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Platelet count >= 100,000/mm3 independent of transfusion support OR >= 50,000/mm3 independent of transfusion\r\nsupport if bone marrow involvement
+Platelet count >= 100,000/mm^3
+Platelet count greater than 100,000/mm^3
+Platelet count greater than or equal to 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count ? 7.5 × 104/mm3
+Lymphocyte count ? 500/mm3
+Platelets > 100,000/mm^3 unless deemed likely related to lymphoma involvement in the bone marrow where minimum allowable platelet count will be 50,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000 mm^-3
+Platelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Platelet count >= 75,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count > 50,000/mm^3 and < 100,000/mm^3 within 14 days prior to study entry
+Platelet count > 100,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count >= 100,000 cells/mm^3
+Platelet count ? 100,000/mm3
+Platelet count > 100000 /mm^3
+Obtained =< 30 days prior to randomization: Platelet count >= 50,000/mm^3
+Platelet count ? 100,000/mm3
+Platelet count >= 25,000 cells/mm^3 (25 x 10^9/L) independent of transfusion within 7 days of screening
+Platelet count > 150,000/mm^3
+Platelet count (PLT) >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count of =< 70,000/mm^3
+Platelet count >= 50,000/mm^3
+Platelet count >50,000/mm³ within 6 weeks screening
+Platelet count >= 100,000/mm^3
+GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment
+Platelet count >= 75,000/mm^3
+Platelet count >= 50,000/mm^3 obtained =< 30 days prior to registration
+Lymphocyte count >= 800/mm^3 within 90 days of enrollment
+Platelet count >= 75,000/mm^3 within 90 days of enrollment
+Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Platelet count > 50,000/mm^3
+Platelet count > 100,000/mm^3
+Platelet count less than (<) 50,000/millimeter^3 (mm^3), Life expectancy of less than or equal to (<=) 6 months
+Platelet count greater than 100,000/mm^3
+Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
+Subject has a platelet count of less than 50,000 mm3 within 3 days prior to randomization (platelet transfusions are allowed)
+Platelet count >= 100,000/mm^3
+Platelet count ? 100,000/mm^3
+- Platelet count of > 50,000/mm3
+Platelet count >= 100,000/mm^3
+Platelet count >= 50/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment
+Platelet dysfunction or platelet count < 100 x 103 cells/mm3
+Platelet count >75,000/ mm3
+Platelet count > 50,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 100,000/mm^3
+Platelet count >= 75,000/mm^3 without transfusion support > 7 days prior to registration
+Platelet count >= 100,000/mm^3 (without transfusion within 2 weeks prior to cycle 1, day 1)
+Platelet ? 100/mm3
+Bone marrow function: neutrophil count >/=1,000/mm3, platelet count >/= 75,000/mm3 and hemoglobin concentration >/= 8.0 g/dL.
+Platelet count >= 100,000/mm^3 (transfusion independent)
+Platelet count >= 100,000/mm^3
+Platelet count > 50,000/mm^3
+- Platelet count of > 50,000/mm3
+Platelet count < 100,000/mm^3
+Platelet counts ?75,000/mm3 (?75×109/L)
+Platelet count > 100,000 cells/mm^3*
+Platelet count >= 75,000/mm^3
+Platelet count > 50,000/mm3
+Platelet count of >= 100,000/mm^3, performed within 28 days prior to registration
+Platelet count >= 100,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
+Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of > 1,500 /mm3 and platelet count >100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial
+Platelet count >=100,000/mm^3.